A novel NF‑κB inhibitor, DHMEQ, ameliorates pristane‑induced lupus in mice

Qu,Huiqing; Bian,Weihua; Xu,Yanyan

doi:10.3892/etm.2014.1718

A novel NF‑κB inhibitor, DHMEQ, ameliorates pristane‑induced lupus in mice

Authors:
- Huiqing Qu
- Weihua Bian
- Yanyan Xu
View Affiliations

Affiliations: Department of Blood Transfusion, Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256603, P.R. China, Department of Biochemistry, Binzhou Medical College, Binzhou, Shandong 256603, P.R. China, Department of Biochemistry, Binzhou Medical College, Binzhou, Shandong 256603, P.R. China
Published online on: May 19, 2014 https://doi.org/10.3892/etm.2014.1718
Pages: 100-104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor (NF)‑κB is strongly associated with the development of immune regulation and inflammation. The aim of the present study was to identify whether a NF‑κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), ameliorates systemic lupus erythematosus (SLE) in a pristane‑induced mouse model. SLE was induced in 8‑week‑old female BALB/c mice by the injection of 0.5 ml pristane. The therapeutic effect of 12 mg/kg DHMEQ on the pristane‑induced BALB/c mouse model of lupus was investigated to elucidate the effects on SLE. The intraperitoneal administration of DHMEQ three times per week was initiated when the mice were 16 weeks‑old (8 weeks following the pristane injection) and the treatment was continued for 16 weeks. Serum IgG autoantibodies against nucleosomes, dsDNA and histones were detected at weeks 8, 16 and 32. In addition, the expression levels of interleukin (IL)‑1β, 6 and 17, as well as tumor necrosis factor (TNF)‑α, were analyzed at week 32. Renal lesions were also observed. DHMEQ was shown to antagonize the increasing levels of anti‑nucleosome, anti‑dsDNA and anti‑histone autoantibodies, as well as the increasing levels of IL‑1β, 6 and 17 and TNF‑α. In addition, DHMEQ reduced the number of renal lesions caused by pristane, as reflected by milder proteinuria and reduced renal pathology. The renal expression levels of phosphorylated‑p38 mitogen‑activated protein kinase (MAPK), phosphorylated‑c‑Jun N‑terminal kinase (JNK) and NF‑κB p65 were significantly downregulated. Therefore, the results of the present study indicate that DHMEQ has a beneficial effect on pristane‑induced lupus through regulating cytokine levels and the MAPK/JNK/NF‑κB signaling pathway.

View Figures

View References

1	Perl A, Fernandez DR, Telarico T, Doherty E, Francis L and Phillips PE: T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol. 21:454–464. 2009. View Article : Google Scholar : PubMed/NCBI
2	Dooley MA, Hogan S, Jennette C and Falk R; Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int. 51:1188–1195. 1997. View Article : Google Scholar : PubMed/NCBI
3	Monneaux F and Muller S: Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther. 11:2342009. View Article : Google Scholar : PubMed/NCBI
4	Kuryłowicz A and Nauman J: The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta Biochim Pol. 55:629–647. 2008.PubMed/NCBI
5	Moynagh PN: The NF-kappaB pathway. J Cell Sci. 118:4589–4592. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kalergis AM, Iruretagoyena MI, Barrientos MJ, et al: Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology. 128(1 Suppl): e306–e314. 2009. View Article : Google Scholar : PubMed/NCBI
7	Feng D, Yang L, Bi X, Stone RC, Patel P and Barnes BJ: Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur J Immunol. 42:1477–1487. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ohsugi T, Horie R, Kumasaka T, et al: In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis. 26:1382–1388. 2005. View Article : Google Scholar : PubMed/NCBI
9	Wellmann U, Letz M, Schneider A, Amann K and Winkler TH: An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1 mice. Int Immunol. 13:1461–1469. 2001.PubMed/NCBI
10	Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C and Ballet JJ: Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 33:24–30. 2006.PubMed/NCBI
11	Hoffmann A, Kerr S, Jellusova J, et al: Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol. 8:695–704. 2007. View Article : Google Scholar : PubMed/NCBI
12	Niculescu F, Nguyen P, Niculescu T, Rus H, Rus V and Via CS: Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Arthritis Rheum. 48:1071–1079. 2003. View Article : Google Scholar
13	Matsumoto N, Ariga A, To-e S, et al: Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 10:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
14	Matsumoto N, Iinuma H, Sawa T, et al: Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II Effect on type II collagen-induced arthritis in mice. J Antibiot (Tokyo). 50:906–911. 1997.PubMed/NCBI
15	Ariga A, Namekawa J, Matsumoto N, Inoue J and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002. View Article : Google Scholar : PubMed/NCBI
16	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
17	Iruretagoyena MI, Tobar JA, González PA, et al: Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther. 312:366–372. 2005. View Article : Google Scholar : PubMed/NCBI
18	Jiang T, Tian F, Zheng H, et al: Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney Int. 85:333–343. 2014.PubMed/NCBI
19	Brown KD, Claudio E and Siebenlist U: The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 10:2122008. View Article : Google Scholar : PubMed/NCBI
20	Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP and Sakkas LI: The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol. 2013:5697512013. View Article : Google Scholar : PubMed/NCBI
21	Jin N, Wang Q, Zhang X, Jiang D, Cheng H and Zhu K: The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Int Immunopharmacol. 11:1319–1326. 2011. View Article : Google Scholar : PubMed/NCBI